How should randomized controlled trials in epithelial ovarian cancer be interpreted?

Int J Gynecol Cancer. 2022 May 3;32(5):693. doi: 10.1136/ijgc-2022-003541.

Authors

Inge Peters¹, Andrea Rosati¹, Giovanni Scambia¹, Anna Fagotti²

Affiliations

¹ Department of Woman's and Child Health and Public Health Sciences, Gynecologic Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
² Department of Woman's and Child Health and Public Health Sciences, Gynecologic Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy anna.fagotti@policlinicogemelli.it.

PMID: 35361682
DOI: 10.1136/ijgc-2022-003541

No abstract available

Keywords: Ovarian Cancer.

Publication types

Comment

MeSH terms

Carcinoma, Ovarian Epithelial / drug therapy
Chemotherapy, Adjuvant
Female
Humans
Ovarian Neoplasms* / drug therapy
Randomized Controlled Trials as Topic